Arcus Biosciences (NYSE:RCUS) Releases Earnings Results

Arcus Biosciences (NYSE:RCUS) posted its earnings results on Tuesday. The company reported ($1.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.17) by $0.14, Zacks reports. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%.

Arcus Biosciences Trading Up 0.9 %

Shares of RCUS opened at $10.26 on Wednesday. Arcus Biosciences has a 52-week low of $10.01 and a 52-week high of $20.31. The stock has a market cap of $1.08 billion, a PE ratio of -3.26 and a beta of 0.84. The firm’s fifty day moving average is $13.67 and its two-hundred day moving average is $15.50. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.08.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on RCUS. Morgan Stanley lowered their price target on Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 18th. Bank of America decreased their target price on Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 19th. Wedbush reissued an “outperform” rating and issued a $36.00 price target on shares of Arcus Biosciences in a report on Thursday, November 7th. Finally, HC Wainwright raised shares of Arcus Biosciences from a “neutral” rating to a “buy” rating and increased their price objective for the company from $18.00 to $24.00 in a report on Wednesday. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $30.25.

Insider Activity

In other news, CFO Robert C. Goeltz II sold 3,594 shares of the business’s stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $15.00, for a total transaction of $53,910.00. Following the transaction, the chief financial officer now directly owns 60,138 shares in the company, valued at $902,070. The trade was a 5.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 12.30% of the company’s stock.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.